Doris Riether

List of Publications by Citations

23 papers	469 citations	14 h-index	21 g-index
27 ext. papers	517 ext. citations	4.5 avg, IF	2.9 L-index

#	Paper	IF	Citations
23	Reactivity of functional groups on the protein surface: development of epoxide probes for protein labeling. *Journal of the American Chemical Society*, **2003**, 125, 8130-3	16.4	98
22	Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics. *Journal of Medicinal Chemistry*, **2010**, 53, 6681-98	8.3	37
21	5-Aminomethylbenzimidazoles as potent ITK antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1588-91	2.9	36
20	Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects. *Journal of Medicinal Chemistry*, **2014**, 57, 1583-98	8.3	27
19	Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-a (BI 665915). *Journal of Medicinal Chemistry*, **2015**, 58, 1868-80	8.3	26
18	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1725-9	2.9	26
17	Efficient synthesis of the D-ring fragment of cobyric acid. *Organic Letters*, **2000**, 2, 3139-41	6.2	26
16	Selective cannabinoid receptor 2 modulators: a patent review 2009--present. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 495-510	6.8	24
15	Total Synthesis of Cobyric Acid: Historical Development and Recent Synthetic Innovations. *European Journal of Organic Chemistry*, **2003**, 2003, 30-45	3.2	21
14	1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2011-6	2.9	19
13	Synthesis of the C-ring fragment of cobyric acid. *Tetrahedron Letters*, **1999**, 40, 6197-6199	2	19
12	Morpholine containing CB2 selective agonists. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1604-9	2.9	18
11	Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. *ACS Medicinal Chemistry Letters*, **2014**, 5, 1318-23	4.3	17
10	Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 575-80	2.9	16
9	Electrochemical Synthesis and Structure Analysis of Neocoenzyme B12 □An Epimer of Coenzyme B12 with a Remarkably Flexible Organometallic Group. *Helvetica Chimica Acta*, **1999**, 82, 848-869	2	14
8	Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 581-6	2.9	11
7	Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1934-40	2.9	10

6	Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 587-92	2.9	9
5	Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4276-80	2.9	9
4	Discovery and optimization of oxadiazole-based FLAP inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4652-4659	2.9	2
3	Epigenetic Modification 6-Methyladenosine Can Impact the Potency and Specificity of siRNA. *ChemBioChem*, **2021**, 22, 491-495	3.8	2
2	Total Synthesis of Cobyric Acid: Historical Development and Recent Synthetic Innovations. *ChemInform*, **2003**, 34, no		1
1	Access to 1aAmino Carbocyclic Phosphoramidite to Enable Postsynthetic Functionalization of Oligonucleotides. *Organic Letters*, **2021**, 23, 6735-6739	6.2	0